January 19, 2016.
Italy’s state-run health service is demanding a money-back guarantee when trying new cancer treatments, Bloomsberg Business reports. The Italian Medicines Agency will pay pharma companies according to how well a patient responds to treatment. In some cases, where the medication fails to help, the drugmaker must provide a full refund. Through this method, approximately 200 million euros ($220 million) was refunded to the Italian government for ineffective treatments last year, amounting to about 1 percent of total pharmaceutical spending. With global oncology expected to reach $100 billion in 2018, Bloomsberg adds that Italy's money-back experiment is being monitored in the U.S. and across Europe. http://www.bloomberg.com/news/articles/2016-01-15/when-new-cancer-treatments-fail-italy-wants-its-money-back
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.